In this edition, lobectomy alternatives show adverse event profiles; frequent CT scans not linked to better surgery outcomes; FDA approves adjuvant Keytruda, and more. Read the full coverage here: Lobectomy alternatives show varying adverse event profiles in early-stage lung cancer More frequent CT scans not linked to better outcomes after lung cancer surgery Osimertinib-related pneumonitis incidence higher in real-world lung cancer population FDA approves adjuvant Keytruda for non-small cell lung cancer Tarlatamab active in recurrent small cell lung cancer References: Heiden BT, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djac208. Paz-Ares L, et al. J Clin Oncol. 2023;doi:10.1200/JCO.22.02823. Press Release Sato Y, et al. CHEST. 2022;doi:10.1016/j.chest.2022.05.035. Wang Q, et al. Ann Am Thorac Soc. 2022;doi:10.1513/AnnalsATS.202203-275OC.

Ver todos los episodios